ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial

Study limitation reported by the research below: “The 0.9 mg cohort was restricted to participants weighing >85 kg, limiting cross-dose comparisons.”